Nobel Biocare has released a response to the recent marketing ban in their NobelDirect implant following reports that it lost an excessive amount of bone following placement. The response called the initial report to the Swedish Medical Products Agency (SMPA) on NobelDirect by Dr Albrektsson as `… incomplete and reported in an unscientific way. The analysis of the present manuscript shows that the material still suffers from intransparency and lack of scientific stringency. The process for peer-review may even be questioned.`
Welcome to OsseoTECH, a site devoted to chronicling osseointegration developments Please send suggestions for features.